Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU gives go-ahead for Roche's Perjeta with further 2013 approvals to follow

This article was originally published in Scrip

Executive Summary

Roche said it anticipates further approvals this year for its targeted breast cancer drug Perjeta (pertuzumab), having secured EU approval for the product to be used in patients with previously untreated HER2-positive metastatic breast cancer (mBC).

You may also be interested in...

Outdated System Preventing Breast Cancer Patients Getting Access To Early Treatment In England, Says Roche

Roche Pharma AG has been scorned once again by the England's health technology appraisal body NICE – with the pricing group this time rejecting the big pharma's breast cancer treatment Perjeta (pertuzumab) for regular use on the NHS as a neoadjuvant therapy.

Topotarget reconfirms mid-2013 US NDA for belinostat as it looks to Q3 milestone

Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).

AstraZeneca wins EU approval of rare thyroid cancer drug vandetanib

AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts